Tango Therapeutics (TNGX) Stock Forecast, Price Target & Predictions
TNGX Stock Forecast
Tango Therapeutics stock forecast is as follows: an average price target of $14.67 (represents a 184.30% upside from TNGX’s last price of $5.16) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
TNGX Price Target
The average price target for Tango Therapeutics (TNGX) is $14.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $13.00. This represents a potential 184.30% upside from TNGX's last price of $5.16.
TNGX Analyst Ratings
According to 4 Wall Street analysts, Tango Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TNGX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Tango Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 17, 2024 | Joseph Catanzaro | Piper Sandler | $18.00 | $8.97 | 100.67% | 248.84% |
| Aug 08, 2024 | Robert Driscoll | Wedbush | $13.00 | $8.72 | 49.08% | 151.94% |
| May 28, 2024 | Robert Burns | H.C. Wainwright | $13.00 | $6.91 | 88.13% | 151.94% |
The latest Tango Therapeutics stock forecast, released on Sep 17, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $18.00, which represents a 100.67% increase from the stock price at the time of the forecast ($8.97), and a 248.84% increase from TNGX last price ($5.16).
Tango Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 3 |
| Avg Price Target | - | $15.50 | $14.67 |
| Last Closing Price | $5.16 | $5.16 | $5.16 |
| Upside/Downside | -100.00% | 200.39% | 184.30% |
In the current month, the average price target of Tango Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Tango Therapeutics's last price of $5.16. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 10, 2024 | Jefferies | Underperform | Underperform | Hold |
| Sep 10, 2024 | Wedbush | Buy | Buy | Hold |
| Sep 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 08, 2024 | Wedbush | Outperform | Outperform | Hold |
| Jul 17, 2024 | Jefferies | - | Buy | Initialise |
| Jul 09, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jul 09, 2024 | Wedbush | Buy | Buy | Hold |
| May 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Tango Therapeutics's last stock rating was published by H.C. Wainwright on Oct 28, 2024. The company gave TNGX a "Buy" rating, the same as its previous rate.
Tango Therapeutics Financial Forecast
Tango Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $10.73M | $14.60M | $5.77M | $6.41M | $6.92M | $5.77M | $5.76M | $12.10M | $6.79M |
| Avg Forecast | $6.99M | $6.99M | $6.99M | $7.60M | $8.47M | $8.07M | $7.63M | $7.50M | $8.24M | $7.59M | $7.19M | $6.77M | $6.32M | $5.64M | $5.66M | $5.83M | $6.57M | $6.51M |
| High Forecast | $6.99M | $6.99M | $6.99M | $7.60M | $8.47M | $12.24M | $7.63M | $7.50M | $11.33M | $7.59M | $7.19M | $6.77M | $6.32M | $5.64M | $5.66M | $5.83M | $6.57M | $6.51M |
| Low Forecast | $6.99M | $6.99M | $6.99M | $7.60M | $8.47M | $5.82M | $7.63M | $7.50M | $6.29M | $7.59M | $7.19M | $6.77M | $6.32M | $5.64M | $5.66M | $5.83M | $6.57M | $6.51M |
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.41% | 2.03% | 0.85% | 1.01% | 1.23% | 1.02% | 0.99% | 1.84% | 1.04% |
Tango Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $8.24M, with a low forecast of $6.29M, and a high forecast of $11.33M. TNGX's average Quarter revenue forecast represents a -23.19% decrease compared to the company's last Quarter revenue of $10.73M (Sep 23).
Tango Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-25.63M | $-23.25M | $-30.29M | $-30.57M | $-29.51M | $-25.20M | $-25.38M | $-34.48M | $-19.53M |
| Avg Forecast | $-6.42M | $-6.42M | $-6.42M | $-6.97M | $-7.77M | $-7.40M | $-7.00M | $-6.89M | $-7.57M | $-6.97M | $-6.60M | $-6.21M | $-5.80M | $-5.18M | $-5.19M | $-5.35M | $-6.03M | $-18.03M |
| High Forecast | $-6.42M | $-6.42M | $-6.42M | $-6.97M | $-7.77M | $-5.34M | $-7.00M | $-6.89M | $-5.78M | $-6.97M | $-6.60M | $-6.21M | $-5.80M | $-5.18M | $-5.19M | $-5.35M | $-6.03M | $-14.42M |
| Low Forecast | $-6.42M | $-6.42M | $-6.42M | $-6.97M | $-7.77M | $-11.23M | $-7.00M | $-6.89M | $-10.40M | $-6.97M | $-6.60M | $-6.21M | $-5.80M | $-5.18M | $-5.19M | $-5.35M | $-6.03M | $-21.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.68% | 3.52% | 4.87% | 5.27% | 5.70% | 4.85% | 4.74% | 5.71% | 1.08% |
undefined analysts predict TNGX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Tango Therapeutics's previous annual EBITDA (undefined) of $NaN.
Tango Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | $-22.26M | $-20.71M | $-25.73M | $-29.06M | $-28.18M | $-24.86M | $-25.04M | $-33.57M | $-19.59M |
| Avg Forecast | $-40.33M | $-39.67M | $-38.16M | $-36.37M | $-41.03M | $-39.72M | $-37.37M | $-33.58M | $-29.68M | $-36.50M | $-35.31M | $-38.09M | $-38.45M | $-34.30M | $-34.23M | $-29.46M | $-28.59M | $-18.08M |
| High Forecast | $-40.33M | $-39.67M | $-38.16M | $-36.37M | $-41.03M | $-35.05M | $-37.37M | $-33.58M | $-26.50M | $-36.50M | $-35.31M | $-38.09M | $-38.45M | $-34.30M | $-34.23M | $-29.46M | $-28.59M | $-14.47M |
| Low Forecast | $-40.33M | $-39.67M | $-38.16M | $-36.37M | $-41.03M | $-44.39M | $-37.37M | $-33.58M | $-33.92M | $-36.50M | $-35.31M | $-38.09M | $-38.45M | $-34.30M | $-34.23M | $-29.46M | $-28.59M | $-21.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.61% | 0.59% | 0.68% | 0.76% | 0.82% | 0.73% | 0.85% | 1.17% | 1.08% |
Tango Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TNGX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Tango Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | $9.21M | $9.17M | $8.01M | $7.89M | $8.10M | $7.23M | $6.81M | $9.29M | $4.43M |
| Avg Forecast | $5.94M | $5.94M | $5.94M | $6.46M | $7.20M | $6.85M | $6.49M | $6.38M | $7.01M | $6.45M | $6.11M | $5.75M | $5.37M | $4.80M | $4.81M | $4.96M | $5.59M | $4.09M |
| High Forecast | $5.94M | $5.94M | $5.94M | $6.46M | $7.20M | $10.40M | $6.49M | $6.38M | $9.63M | $6.45M | $6.11M | $5.75M | $5.37M | $4.80M | $4.81M | $4.96M | $5.59M | $4.91M |
| Low Forecast | $5.94M | $5.94M | $5.94M | $6.46M | $7.20M | $4.94M | $6.49M | $6.38M | $5.35M | $6.45M | $6.11M | $5.75M | $5.37M | $4.80M | $4.81M | $4.96M | $5.59M | $3.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.43% | 1.50% | 1.39% | 1.47% | 1.69% | 1.50% | 1.37% | 1.66% | 1.08% |
Tango Therapeutics's average Quarter SG&A projection for Dec 23 is $7.01M, based on 6 Wall Street analysts, with a range of $5.35M to $9.63M. The forecast indicates a -23.93% fall compared to TNGX last annual SG&A of $9.21M (Sep 23).
Tango Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.23 | $-0.23 | $-0.29 | $-0.33 | $-0.32 | $-0.28 | $-0.29 | $-0.38 | $-0.28 |
| Avg Forecast | $-0.37 | $-0.37 | $-0.35 | $-0.34 | $-0.38 | $-0.37 | $-0.34 | $-0.31 | $-0.27 | $-0.34 | $-0.33 | $-0.35 | $-0.35 | $-0.32 | $-0.32 | $-0.27 | $-0.26 | $-0.28 |
| High Forecast | $-0.37 | $-0.37 | $-0.35 | $-0.34 | $-0.38 | $-0.32 | $-0.34 | $-0.31 | $-0.24 | $-0.34 | $-0.33 | $-0.35 | $-0.35 | $-0.32 | $-0.32 | $-0.27 | $-0.26 | $-0.28 |
| Low Forecast | $-0.37 | $-0.37 | $-0.35 | $-0.34 | $-0.38 | $-0.41 | $-0.34 | $-0.31 | $-0.31 | $-0.34 | $-0.33 | $-0.35 | $-0.35 | $-0.32 | $-0.32 | $-0.27 | $-0.26 | $-0.28 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.68% | 0.71% | 0.82% | 0.93% | 1.01% | 0.89% | 1.07% | 1.44% | 0.99% |
According to undefined Wall Street analysts, Tango Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TNGX previous annual EPS of $NaN (undefined).
Tango Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| RAPT | RAPT Therapeutics | $2.27 | $42.20 | 1759.03% | Hold |
| STTK | Shattuck Labs | $1.16 | $12.00 | 934.48% | Hold |
| PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
| BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
| XLO | Xilio Therapeutics | $1.44 | $7.00 | 386.11% | Buy |
| RLAY | Relay Therapeutics | $5.85 | $19.40 | 231.62% | Buy |
| TNGX | Tango Therapeutics | $5.16 | $14.67 | 184.30% | Buy |
| PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
| ARVN | Arvinas | $26.80 | $71.82 | 167.99% | Buy |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| FHTX | Foghorn Therapeutics | $8.24 | $16.33 | 98.18% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| TYRA | Tyra Biosciences | $16.42 | $30.50 | 85.75% | Buy |
| THRD | Third Harmonic Bio | $12.11 | $16.15 | 33.36% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| NRIX | Nurix Therapeutics | $25.04 | $32.20 | 28.59% | Buy |
| CNTB | Connect Biopharma | $1.20 | $1.50 | 25.00% | Buy |
| KYMR | Kymera Therapeutics | $47.07 | $51.50 | 9.41% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
TNGX Forecast FAQ
Is Tango Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Tango Therapeutics (TNGX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of TNGX's total ratings.
What is TNGX's price target?
Tango Therapeutics (TNGX) average price target is $14.67 with a range of $13 to $18, implying a 184.30% from its last price of $5.16. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Tango Therapeutics stock go up soon?
According to Wall Street analysts' prediction for TNGX stock, the company can go up by 184.30% (from the last price of $5.16 to the average price target of $14.67), up by 248.84% based on the highest stock price target, and up by 151.94% based on the lowest stock price target.
Can Tango Therapeutics stock reach $8?
TNGX's average twelve months analyst stock price target of $14.67 supports the claim that Tango Therapeutics can reach $8 in the near future.
What are Tango Therapeutics's analysts' financial forecasts?
Tango Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $31.67M (high $35.84M, low $29.42M), average EBITDA is $-29.065M (high $-27.002M, low $-32.895M), average net income is $-152M (high $-147M, low $-156M), average SG&A $26.91M (high $30.46M, low $25M), and average EPS is $-1.401 (high $-1.357, low $-1.444). TNGX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $28.57M (high $28.57M, low $28.57M), average EBITDA is $-26.223M (high $-26.223M, low $-26.223M), average net income is $-155M (high $-155M, low $-155M), average SG&A $24.28M (high $24.28M, low $24.28M), and average EPS is $-1.427 (high $-1.427, low $-1.427).
Did the TNGX's actual financial results beat the analysts' financial forecasts?
Based on Tango Therapeutics's last annual report (Dec 2023), the company's revenue was $36.53M, beating the average analysts forecast of $29.79M by 22.61%. Apple's EBITDA was $-114M, beating the average prediction of $-27.343M by 317.56%. The company's net income was $-102M, missing the average estimation of $-140M by -27.11%. Apple's SG&A was $35.5M, beating the average forecast of $25.32M by 40.23%. Lastly, the company's EPS was $-1.08, missing the average prediction of $-1.289 by -16.19%. In terms of the last quarterly report (Sep 2023), Tango Therapeutics's revenue was $10.73M, beating the average analysts' forecast of $7.59M by 41.40%. The company's EBITDA was $-25.626M, beating the average prediction of $-6.966M by 267.86%. Tango Therapeutics's net income was $-22.263M, missing the average estimation of $-36.502M by -39.01%. The company's SG&A was $9.21M, beating the average forecast of $6.45M by 42.77%. Lastly, the company's EPS was $-0.23, missing the average prediction of $-0.337 by -31.75%